Kymera Therapeutics, Inc. (KYMR) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Kymera Therapeutics, Inc. (KYMR) Earnings Overview
As of October 3, 2026, Kymera Therapeutics, Inc. (KYMR) reported trailing twelve-month net income of -$300M, reflecting -23.8% year-over-year growth. The company earned $-3.05 per diluted share over the past four quarters, with a net profit margin of -794.4%.
Looking at the long-term picture, KYMR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$21M in fiscal 2018.
Kymera Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARVN ($9M net income, -30.8% margin), PRAX (-$339M net income), VKTX (-$535M net income), KYMR has room to improve margins relative to the peer group. Compare KYMR vs ARVN →
KYMR Earnings vs Peers
Earnings metrics vs comparable public companies
KYMR Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$311M | -39.1% | -$349M | $-3.69 | -794.4% | -891.3% |
| 2024 | -$224M | -52.3% | -$262M | $-2.98 | -475.6% | -555.8% |
| 2023 | -$147M | +5.1% | -$166M | $-2.52 | -187.0% | -210.6% |
| 2022 | -$155M | -54.5% | -$161M | $-2.87 | -330.6% | -344.4% |
| 2021 | -$100M | -119.8% | -$101M | $-2.09 | -137.6% | -138.0% |
| 2020 | -$46M | -10.4% | -$46M | $-0.99 | -134.0% | -136.1% |
| 2019 | -$41M | -92.4% | -$42M | $-0.93 | -1407.4% | -1438.5% |
| 2018 | -$21M | - | -$21M | $-0.48 | - | - |
Download Data
Export KYMR earnings history in CSV or JSON format
Free sign-in required to download data
KYMR Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KYMR — Frequently Asked Questions
Quick answers to the most common questions about buying KYMR stock.
What is KYMR earnings per share (EPS)?
KYMR trailing twelve-month (TTM) diluted EPS is $-3.05, reflecting -23.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Kymera Therapeutics, Inc.'s net income?
Kymera Therapeutics, Inc. (KYMR) trailing twelve-month net income is $-300M as of 2025. Earnings declined -23.8% year-over-year.
Is KYMR profitable?
KYMR is not currently profitable on a TTM basis, reporting a net loss of $-300M. Net margin is -794.4%. Investors should monitor for a return to profitability.
What is KYMR's earnings growth rate?
KYMR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are KYMR's profit margins?
Kymera Therapeutics, Inc. net profit margin is -794.4%, operating margin is -891.3%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -25.8%.
Is KYMR growing earnings?
KYMR earnings are declining — EPS fell -23.8% year-over-year. TTM net income dropped to $-300M. This contrasts with the 5-year CAGR of N/A.
What was KYMR's best earnings year?
Kymera Therapeutics, Inc.'s highest annual net income on record is $-21M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were KYMR's earnings last quarter?
KYMR's most recent reported quarter was Q2 2026. Net income was $-61M with diluted EPS of $-0.62. For a full breakdown of all quarters, see the quarterly earnings table on this page.